Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation.

scientific article published in July 2005

Defining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.CHEMBIOL.2005.05.011
P698PubMed publication ID16039528
P5875ResearchGate publication ID7705028

P50authorKenneth S. KosikQ6390661
Andrea MusacchioQ17715087
B TidorQ67689738
Jae Suk AhnQ125308805
P2093author name stringMarina Mapelli
Gregory D Cuny
Sungwoon Choi
Mala L Radhakrishnan
Li-An Yeh
P2860cites workCrystallography & NMR System: A New Software Suite for Macromolecular Structure DeterminationQ26778405
P433issue7
P921main subjectphosphorylationQ242736
P304page(s)811-823
P577publication date2005-07-01
P1433published inChemistry and BiologyQ15758410
P1476titleDefining Cdk5 ligand chemical space with small molecule inhibitors of tau phosphorylation
P478volume12

Reverse relations

cites work (P2860)
Q52575762A Novel Method for Drug Screen to Regulate G Protein-Coupled Receptors in the Metabolic Network of Alzheimer's Disease.
Q38023859Biochemistry and cell biology of tau protein in neurofibrillary degeneration
Q47873426CDK5 in oncology: recent advances and future prospects.
Q64098935Computational Simulations Identified Two Candidate Inhibitors of Cdk5/p25 to Abrogate Tau-associated Neurological Disorders
Q64930625Computational Simulations Identify Pyrrolidine-2,3-Dione Derivatives as Novel Inhibitors of Cdk5/p25 Complex to Attenuate Alzheimer's Pathology.
Q33566835Designing of dual inhibitors for GSK-3β and CDK5: Virtual screening and in vitro biological activities study
Q27677453Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent Kinases
Q37048487Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models
Q46890342Different mechanisms of CDK5 and CDK2 activation as revealed by CDK5/p25 and CDK2/cyclin A dynamics
Q34625383Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening
Q57279319Identification and characterization of a novel phosphoregulatory site on cyclin-dependent kinase 5
Q38760031Kinase targets in CNS drug discovery.
Q28533443Molecular basis of differential selectivity of cyclobutyl-substituted imidazole inhibitors against CDKs: insights for rational drug design
Q54549089Multiple drugs and multiple targets: an analysis of the electrostatic determinants of binding between non-nucleoside HIV-1 reverse transcriptase inhibitors and variants of HIV-1 RT.
Q36600358New directions for frontotemporal dementia drug discovery
Q33733724No difference in kinetics of tau or histone phosphorylation by CDK5/p25 versus CDK5/p35 in vitro
Q30481896Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants
Q36543455Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems
Q37289231Structural basis for the different stability and activity between the Cdk5 complexes with p35 and p39 activators
Q34706737Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors
Q47423882Structure-based discovery of cyclin-dependent protein kinase inhibitors.
Q33880243The role of the lipid bilayer in tau aggregation
Q81527536Therapeutic strategies for Alzheimer's disease
Q36836607Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases.

Search more.